PERSONETICS
KBC, a leading multi-channel bank-insurance group with a geographic focus in Europe, has partnered with Personetics , the leading global provider of financial-data-driven personalization and customer engagement solutions for financial services. The companies will be working together to deliver multi-lingual, proactive, data-driven solutions to increase customer engagement on KBC's mobile application to meet customer needs.
Personetics AI models use customers' financial data to automatically configure and categorize all transactions, simplifying and greatly improving the user experience. Personetics provides KBC with a powerful Engagement Builder Platform, "Engage," to enable KBC to modify existing and create ongoing insights and recommendations for customers. As a result of implementing Engage, KBC saw a clear rise in engagement, including high opt-in and session use above industry benchmarks with a +90% satisfaction rating.
“Exceeding customer expectations of KBC Mobile is what excites our team. One way of achieving this is through saving time & money. For example: getting a quick heads-up to check if a double payment was intended. Or a notification when you received a payment, in the likes of a tax return. Each time we are able to provide such relevant information, it may give a small, but tangible benefit to the customers' life and add to his or her personal financial insight. Personetics is helping us achieve that type of relevance,” says Karin Van Hoecke, General Manager (Digital) Transformation and Data at KBC.
"Personetics' Engage solution provides us with both flexibility and scale. With their broad catalog of proven valuable and relevant insights, we could develop and extend our PFM solution much quicker than if we would have built everything from scratch ourselves. In addition, we also benefitted from Personetics' extensive hands-on experience with their banking customers. With Personetics' brand-new Engagement Builder, we received a powerful tool that provides us with even more flexibility than before. It will allow us to design custom insights without the need to develop them manually. This will help us to differentiate our PFM solution from those of our competitors."
- Jurgen Indekeu, Policy Advisor for Mass Retail segment at KBC
"KBC's usage numbers show us, yet again, that customers are hungry for relevant, succinct information about their finances. When their bank-insurer delivers that information through customized, helpful insights, they're much more likely to engage over time," says David Sosna, CEO of Personetics.
KBC Belgium and Personetics in numbers:
- Bank assets: €320 billion
- Bank clients in Belgium: 2.6 million
- Bank digital users in Belgium: Approx. 1.6 million
- Partner since 2018
- Customer satisfaction of personalized insights: +90%
- Insights generated over time: 47.4 million
- Average of 6 new insights per customer per month
- Personetics Active Engagement: 35%
- Languages: Dutch, English, French, German
The partnership agreement between Personetics and KBC is projected further to validate KBC as a leading European Financial Institution. Additional services and functionalities are expected to be rolled out in the coming months, with KBC adding Personetics functionality for their Small and Midsize Business clients to strengthen KBC's personalized engagement offering across the board.
The detailed Case Study about the partnership can be accessed by clicking here
About Personetics:
Focused on enabling proactive engagement for banks, Personetics' AI analyzes financial data in real-time to understand customer financial behavior, anticipate customer needs and deliver a hyper-personalized experience. With solutions designed for the mass retail market, wealth management, and small business customers, Personetics' technology enables banks to offer day-to-day insights, financial advice, and automated wellness programs. Banks use Personetics' agile platform to rapidly create their personalization IP to serve the unique needs of their customers and differentiate themselves in a crowded market. With these advances, banks have transformed their digital banking into the center of the customers' financial lives while also delivering significant business impact.
Led by a team of seasoned financial and technology entrepreneurs, Personetics strives to actualize a world of "Self-Driving Finance" where banks proactively act on behalf of their customers – a win-win for customers and banks alike. Founded in 2011, Personetics operates through offices in New York, London, Paris, Singapore, and Tel Aviv. To learn more, visit www.personetics.com .
About KBC:
KBC is one of the leading financial groups in Europe. It is a multi-channel bank-insurance group with a geographic focus on Europe, catering mainly to retail clients, SMEs and local midcaps. The group occupies significant, and in many cases leading positions in its core markets of Belgium, Czech Republic, Bulgaria, Hungary, Slovakia and Ireland. The KBC group has also selectively established a presence in a number of other countries and regions around the world.
KBC employs around 41000 staff and caters for about 12 million clients in its core markets. KBC Group NV is listed on Euronext Brussels (ticker symbol 'KBC').
KBC's mission is to be among Europe's best-performing financial institutions. By achieving this, KBC wants to become the reference in bank insurance in its core markets.
"We want to enable and protect the dreams of our clients. We want to inspire, boost, and stimulate those who count on us, day after day." To realize this vision, KBC seeks to increase customer engagement by continuously upgrading /finetuning /further adapting and improving its mobile application to evolving customer needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005972/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
